Histogen Inc

NASDAQ:HSTO   3:55:37 PM EDT
0.44
-0.04 (-7.58%)
Products

Histogen Inc Says Top-Line Data For Phase 1 Study Of Emricasan In Mild-Symptomatic Covid-19 Patients Anticipated In June 2021

Published: 06/03/2021 12:30 GMT
Histogen Inc (HSTO) - Histogen Inc - Top-line Data for Phase 1 Study of Emricasan in Mild-symptomatic Covid-19 Patients Anticipated in June 2021.
Histogen Inc - Hst 004 Selected As Product Candidate for Spinal Disc Repair With Ind Enabling Activities Underway.
Histogen Inc - Hst 003 Trial for Cartilage Regeneration in Knee Remains On-track With an Anticipated Phase 1/2 Study Initiation in June 2021.